APAC WEBINAR SERIES

Long-Read Sequencing for Comprehensive Genetic Disease Screening

Wednesday, 20 August 2025
1:00 - 2:00 pm (Singapore Standard Time)
2:00 – 3:00 pm (Seoul, Tokyo)
3:00-4:00 pm (Melbourne)

Join us on Wednesday, 20 August 2025 from 1:00 - 2:00 pm (Singapore Time) for the second PacBio Asia Pacifc webinar series featuring Dr. Aiping Mao Director, Department of R&D from Berry Genomics.

Advances in genetic screening have transformed our ability to detect rare and inherited diseases. However, traditional short-read sequencing methods struggle with complex loci, structural variants, and mosaicism—leading to missed or ambiguous diagnoses, especially in diseases with diverse genetic backgrounds.

In this webinar, Dr. Mao Aiping from Berry Genomics will introduce a suite of long-read sequencing panels designed for comprehensive analysis of challenging genetic disorders. These include thalassemia, congenital adrenal hyperplasia (CAH), spinal muscular atrophy (SMA), and fragile X syndrome—diseases that require precise resolution of deletions, duplications, pseudogenes, and complex mutations.

From carrier screening to prenatal and newborn diagnostics, Dr. Mao Aiping will demonstrate how long-read sequencing enables one-shot, high-resolution detection across multiple disease types, setting a new standard in clinical genomics.

Key Takeaways​:

  • Understand the limitations of conventional sequencing for complex genetic loci

  • Explore real world case studies in thalassemia, CAH, SMA, and fragile-X syndrome

  • Learn how long-read sequencing panels simplify workflows across multiple diseases​

  • See how CATSA, CACAH, CASMA, and CAFXs panels enable carrier, prenatal, and newborn screening​

  • Discover how multi-disease LRS panels support public health programs and precision prevention

Dr. Aiping Mao, Director, Department of R&D, Berry Genomics Corporation

Dr. Aiping Mao got her PhD degree in Cell Biology from Wuhan University and had worked as a postdoc for Immunology in University of Chicago. Since Oct 2017, Dr. Mao joined Berry Genomics, a Chinese company committed to the comprehensive transformation of genetic testing technologies including long-read sequencing into clinical application, focusing on reproductive health, genetic disease testing. Dr. Mao leads the R&D and Clinical Research teams, is well-known for her pioneering work in developing a serial of long-read sequencing-based assays for complicated monogenic diseases like thalassemia, CAH, SMA, and FXS etc, and applying these assays in large-scale clinical application.

Register Now!

By registering on this web page, you are consenting and agreeing to collection and use of that information by PacBio in accordance with its Privacy Policy.

Speakers

Dr. Aiping Mao

Director, Department of R&D
Berry Genomics Corporation

Liang Weng

Manager, Regional Marketing, China
PacBio
Moderator